Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05

Trial Profile

An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2019

At a glance

  • Drugs Talimogene laherparepvec (Primary) ; Granulocyte colony-stimulating factors
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms OPTIM-extension
  • Sponsors BioVex
  • Most Recent Events

    • 08 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Feb 2015 Status changed from recruiting to active, no longer recruiting, according to M.D. Anderson Cancer Center.
    • 06 Mar 2013 Actual initiation date changed from Oct 2010 to 8 Feb 2012 as reported by Vanderbilt-Ingram Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top